Innate Pharma S.A.
IPHYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $227 | $216 | $243 | $304 |
| - Cash | $66 | $71 | $84 | $104 |
| + Debt | $31 | $40 | $42 | $44 |
| Enterprise Value | $192 | $185 | $201 | $245 |
| Revenue | $13 | $62 | $50 | $12 |
| % Growth | -79.5% | 24.2% | 309.8% | – |
| Gross Profit | $13 | $6 | $6 | -$22 |
| % Margin | 100% | 9.1% | 12.1% | -184.1% |
| EBITDA | -$47 | -$8 | -$12 | -$43 |
| % Margin | -371.7% | -12.3% | -24.7% | -356.9% |
| Net Income | -$49 | -$8 | -$58 | -$53 |
| % Margin | -392% | -12.3% | -117.1% | -436% |
| EPS Diluted | -0.61 | -0.09 | -0.73 | -0.57 |
| % Growth | -577.8% | 87.7% | -28.1% | – |
| Operating Cash Flow | -$7 | -$33 | -$19 | -$58 |
| Capital Expenditures | -$0 | -$2 | -$1 | -$1 |
| Free Cash Flow | -$7 | -$35 | -$20 | -$60 |